

### Emerging understanding of chronic itchy skin diseases—shared and unique drivers in AD, PN, and CSU

- The chronic skin conditions AD, PN, and CSU have distinct clinical features but share the symptom of intense pruritus1-5
- In each disease, a distinct combination of type 2 inflammatory cells and cytokines interact with cells of the neuroimmune axis leading to itch, and with structural skin cells leading to the cutaneous signs of each disease



#### Atopic dermatitis

Barrier dysfunction<sup>6-8</sup>

Increased risk of infections

Eczematous lesions<sup>1</sup>

Inflammatory chronic itch<sup>7,9</sup>

Fibrosis<sup>10</sup>

Papulonodular lesions<sup>2,10</sup>

Scarring<sup>2,10</sup>

Type 2 inflammation<sup>6</sup> Neurogenic and inflammatory chronic itch<sup>2,9</sup>

Vasodilation and increased vascular permeability<sup>11,12</sup>

Transient wheals that itch3,4,9

Angioedema<sup>3,4</sup>



Chronic spontaneous urticaria

nodularis



A deeper understanding of the pathophysiology that contributes to the distinct clinical features and the common symptom of itch will help to address the burden of these chronic pruritic conditions.

AD, atopic dermatitis; CSU, chronic spontaneous urticaria; PN, prurigo nodularis.

- 1. Weidinger S, et al. Nat Rev Dis Primers. 2018;41. 2. Misery L. Br. J Dermatol. 2022;187:464-471. 3. Zuberbier T, et al. Allergy. 2022;77:734-766. 4. Konstantinou GN, et al. J Allergy Clin Immunol Pract. 2023;11:94-106. 5. Kwatra SG, et al. Clin Transl Immunol. 2022;11(5):e1390. 6. Haddad EB, et al. Dermatol Ther (Heidelb). 2022;12:1501-1533.
- 7. Beck LA, et al. JID Innov. 2022;2:100131. 8. Tominaga M, et al. Allergol Int. 2022;71:265–277. 9. Garcovich S, et al. Vaccines (Basel). 2021;9:303 10. Weigelt N, et al. J Cutan Pathol. 2010;37:578-586. 11. Kolkhir P, et al. Nat Rev Dis Primers. 2022;8:61. 12. Wernersson S, Pejler G. Nat Rev Immunol. 2014;14:478-494.

ADVENTprogram.com





# ADVENT is a breakthrough educational program bringing together different specialties treating patients with type 2 inflammatory diseases.

Prof. Thomas Bieber, Dermatologist, Germany



## What is the ADVENT program?

ADVENT is a global medical education program that shares the latest evidence on diseases with underlying type 2 inflammation

#### Areas covered include:

#### **DERMATOLOGY**

Atopic dermatitis
Prurigo nodularis
Chronic spontaneous urticaria

#### **RESPIRATORY**

Asthma
Chronic rhinosinusitis
with nasal polyps

#### **GASTROENTEROLOGY**

Eosinophilic esophagitis

#### Goals of the platform



Improve patient care



Facilitate cross-specialty knowledge sharing



Explore multidisciplinary implications of underlying type 2 inflammation



Reduce the burden of diseases driven by underlying type 2 inflammation

## What does ADVENT have to offer?

## ADVENT materials were developed with:



More than 120 experts from more than 15 countries



Specialists in **allergy**, **dermatology**, **gastroenterology**, **otolaryngology** and **respiratory** medicine

#### The ADVENT program provides:



On-demand events



Expert presentations



Self-guided educational resources



Expert interviews



Infographics



Activities adapted for local needs and languages



STAY IN THE KNOW ABOUT THE EVOLVING SCIENCE OF TYPE 2 INFLAMMATION For more information visit ADVENTprogram.com

